MTOR and acute lymphoblastic leukemia: These data suggest that combinations of JAK2 and mTOR inhibitors induce synergistic antileukemia activity in Ph-like ALL cells, and that blockade of mTOR signaling can partially reverse resistance to ruxolitinib, further enhancing sensitivity to BBT594.